

# US Industry Sector M&A & Valuation TLDR - 2025-12-22

*US Industry Sector*

*Generated on 2025-12-22*

*CONFIDENTIAL - FOR INTERNAL USE ONLY*

## 1. 30-Second TL;DR

---

- Alnylam Pharmaceuticals is investing \$250 million to expand its manufacturing facility, enhancing its RNAi therapeutic capabilities.
- NeuroSigma has completed a \$1 million investment to boost production for its Monarch eTNS device, targeting ADHD treatment.
- The industrial sector shows mixed sentiment, with aerospace and defense performing well, while automotive faces challenges. Current EV/EBITDA multiples average around 10.2x, reflecting varied growth prospects.

## 2. 1-Minute TL;DR

---

- Alnylam Pharmaceuticals announced a \$250 million investment to expand its manufacturing facility, aiming to enhance production capacity for RNAi therapeutics. This strategic move is designed to meet growing global demand and lower production costs.
- NeuroSigma has completed a \$1 million investment to improve manufacturing for its second-generation Monarch eTNS device, which offers a non-stimulant ADHD treatment alternative.
- The industrial sector is characterized by mixed performance: aerospace and defense are thriving, while the automotive industry grapples with supply chain issues. Current EV/EBITDA multiples average around 10.2x, indicating cautious investor sentiment amid regulatory scrutiny and economic uncertainties.

## 3. 2-Minute TL;DR

---

- Alnylam Pharmaceuticals is investing \$250 million in a new manufacturing facility to enhance its RNA interference (RNAi) therapeutic capabilities. This expansion is crucial for meeting the increasing global demand for innovative treatments for genetic diseases. However, risks include regulatory challenges and market competition.
- NeuroSigma has completed a \$1 million investment to establish a high-volume manufacturing line for its Monarch eTNS device, aimed at providing a non-stimulant ADHD treatment. This investment is

# US Industry Sector M&A & Valuation TLDR - 2025-12-22

## *US Industry Sector*

expected to improve production efficiency, although it carries risks related to reliance on a single manufacturing partner.

- The industrial sector is navigating a complex landscape, with aerospace and defense sectors showing resilience due to increased spending and technological advancements. In contrast, the automotive industry is facing challenges from supply chain disruptions and the shift towards electric vehicles. Current trading multiples reflect this mixed sentiment, with an average EV/EBITDA of 10.2x across the sector.

- Key market drivers include digital transformation and robust investment in industrial automation, while headwinds consist of regulatory scrutiny and economic uncertainties. Investors are advised to focus on high-growth areas and monitor regulatory developments closely.